• Contemporary ClinicContemporary Clinic
  • OTC GuideOTC Guide
  • Pharmacy Times
  • PTCEPTCE
  • Pharmacist Moms GroupPharmacist Moms Group
News
All News
FDA Updates
Press Releases
Media
All Videos
Digital Detail
Independent Corner
Insights
Interviews
MEDcast
Medical World News
Microsites
Peer Exchange
Perfect Consult
Podcasts
Practice Pearls
Sponsored Webcast
Student Voices
Webinars/Webcasts
Conferences
Conference Coverage
Conference Listing
Publications
Pharmacy Times
Pharmacy Practice in Focus: Oncology
Pharmacy Practice in Focus: Health Systems
Pharmacy Careers
All Publications
About the Publications
Author Submission
Submit to Pharmacy Practice in Focus: Oncology
Submit to Pharmacy Practice in Focus: Health Systems
Become a Peer Reviewer
Supplements & Featured Publications
Clinical
503B Compounding Pharmacy
ADHD
Allergy
Alzheimer Disease
Anxiety
Asthma
Atopic Dermatitis
Biosimilars
Bipolar Disorder
Brain Health
Breast Cancer
C. Difficile
COPD
Cardiovascular Health
Cervical Cancer
Cholangiocarcinoma
Cholesterol
Chronic Kidney Disease
Chronic Lymphocytic Leukemia
Classical Hematology
Colorectal Cancer
Continuous Glucose Monitoring
Coronavirus
Cough and Cold
Depression
Dermatology
Diabetes
Digestive Health
Dry Eye Disease
Epilepsy
Eye Care
Flu
Future of Pharmacy
Gastrointestinal Cancer
Gastrointestinal Health
Gout
HER2 Breast Cancer
HIV
Heart Failure
Hematology
Hepatitis/MASH
IVIG
Immunization
Immuno-oncology
Infectious Disease
Lung Cancer
Lymphoma
Macular Degeneration
Mental Health
Migraine
Multiple Myeloma
Multiple Sclerosis
Myelofibrosis
Neurology
Neutropenia
Osteoporosis
Ovarian Cancer
Pain Management
Parkinson Disease
Pediatrics
Pharmacy Heroes
Pharmacy Management
Pneumococcal
PrEP
Prostate Cancer
Psoriasis
Psoriatic Arthritis
Psychedelics
Reimbursement
Reproductive Health
Respiratory Syncytial Virus
Rheumatoid Arthritis
Schizophrenia
Shingles
Skin Cancer
Sleep
Travel Vaccines
Veterinary Pharmacy
Vitamins and Supplements
Weight Management
Women's Health
Events
Upcoming Events
Upcoming Webinars
CE
Resources
Clinical Forum
Cou-Co
Educated Patient
Information for the Pharmacist
Interactive Tools
Partners
Sponsored
Whiteboards
Subscribe
logo
Spotlight
Community/RetailHospitalOncologyPharmacy TechnicianStudent
Clinical Role
Community/RetailHospitalOncologyPharmacy TechnicianSpecialty PharmacyStudent
Clinical
CoronavirusBrain HealthCardiovascular HealthDermatologyDiabetesFluHeart FailureHepatitis/MASHImmunizationMigrainePneumococcalVitamins and Supplements
Supplement Spotlight
October 2023 Pharmacy Technician Edition
All News
FDA Updates
Press Releases
All Videos
Digital Detail
Independent Corner
Insights
Interviews
MEDcast
Medical World News
Microsites
Peer Exchange
Perfect Consult
Podcasts
Practice Pearls
Sponsored Webcast
Student Voices
Webinars/Webcasts
Conference Coverage
Conference Listing
Pharmacy Times
Pharmacy Practice in Focus: Oncology
Pharmacy Practice in Focus: Health Systems
Pharmacy Careers
All Publications
About the Publications
Author Submission
Submit to Pharmacy Practice in Focus: Oncology
Submit to Pharmacy Practice in Focus: Health Systems
Become a Peer Reviewer
Supplements & Featured Publications
503B Compounding Pharmacy
ADHD
Allergy
Alzheimer Disease
Anxiety
Asthma
Atopic Dermatitis
Biosimilars
Bipolar Disorder
Brain Health
Breast Cancer
C. Difficile
COPD
Cardiovascular Health
Cervical Cancer
Cholangiocarcinoma
Cholesterol
Chronic Kidney Disease
Chronic Lymphocytic Leukemia
Classical Hematology
Colorectal Cancer
Continuous Glucose Monitoring
Coronavirus
Cough and Cold
Depression
Dermatology
Diabetes
Digestive Health
Dry Eye Disease
Epilepsy
Eye Care
Flu
Future of Pharmacy
Gastrointestinal Cancer
Gastrointestinal Health
Gout
HER2 Breast Cancer
HIV
Heart Failure
Hematology
Hepatitis/MASH
IVIG
Immunization
Immuno-oncology
Infectious Disease
Lung Cancer
Lymphoma
Macular Degeneration
Mental Health
Migraine
Multiple Myeloma
Multiple Sclerosis
Myelofibrosis
Neurology
Neutropenia
Osteoporosis
Ovarian Cancer
Pain Management
Parkinson Disease
Pediatrics
Pharmacy Heroes
Pharmacy Management
Pneumococcal
PrEP
Prostate Cancer
Psoriasis
Psoriatic Arthritis
Psychedelics
Reimbursement
Reproductive Health
Respiratory Syncytial Virus
Rheumatoid Arthritis
Schizophrenia
Shingles
Skin Cancer
Sleep
Travel Vaccines
Veterinary Pharmacy
Vitamins and Supplements
Weight Management
Women's Health
Upcoming Events
Upcoming Webinars
CE
Clinical Forum
Cou-Co
Educated Patient
Information for the Pharmacist
Interactive Tools
Partners
Sponsored
Whiteboards
Subscribe
Advertisement

CLINICAL ROLE -

Community/Retail
| Hospital
| Oncology
| Pharmacy Technician
| Student

Article

December 5, 2014

Guideline-Recommended Treatments for Symptomatic and Generalized Epilepsies

Author(s):

Michael R. Page, PharmD, RPh
Conference|AES Annual Meeting - American Epilepsy Society Annual Meeting

Understanding the recommendations of evidence-based guidelines is an important component of treating patients with therapies backed by the best available evidence.

Understanding the recommendations of evidence-based guidelines is an important component of treating patients with therapies backed by the best available evidence.

Sandra L. Helmers, MD, MPH, discussed the treatment of generalized epilepsies at the 68th annual meeting of the American Epilepsy Society in Seattle, Washington. Although many treatments for epilepsy have been developed and approved, many types of epilepsies exist, and the treatment of different types of epilepsy varies.

In general, epilepsies may be focal or generalized, and may or may not be associated with neurodevelopmental abnormalities that are visible on magnetic resonance imaging scans.1 Goals of treatment for symptomatic and progressive generalized epilepsies include optimizing seizures control, minimizing adverse events, and improving quality of life. Patients with epilepsy are typically refractory to treatment, and generally do not experience complete control of epilepsy episodes with therapy.

Commonly used treatment modalities for generalized epilepsy include anticonvulsants, neurostimulation therapy, dietary control measures, and brain surgery. Some patients may also receive other complementary therapies.

Guidelines for the selection of antiepileptic drugs (AEDs) include 2 types of guidelines: those that are solely based on evidence, and other guidelines that rely on expert opinion, surveys, or the Delphi method in a group of experts.

Evidence-based guidelines include:

· The International League Against Epilepsy (ILAE) Guidelines2

· The National Institute for Clinical Excellence Guidelines3

· The American Academy of Neurology and American Epilepsy Society (AAN/AES) Guidelines4

· The Scottish Intercollegiate Guidelines Network Guidelines5

· The Status Epilepticus (SE) Working Group Guidelines6

Of these guidelines, the most widely accepted and up-to-date guideline used by US health care professionals is the ILAE Guideline. Regarding guideline-recommended treatments, it is notable that not all epilepsies have treatments supported by high-quality evidence. Evidence quality is classified as level A (highest quality), B (intermediate quality), or C (lower quality).

For children with generalized-onset tonic-clonic seizures, children with absence seizures, patients with benign epilepsy with centro-temporal spikes, adults and children with generalized tonic-clonic seizures, and patients with absence seizures, available guideline-recommended treatments are supported only by level C evidence. In one condition, juvenile myoclonic epilepsy, no available treatments recommended by guidelines are supported by any level A through C evidence. The only epilepsy disease state with recommended treatments backed by level A or B evidence is partial-onset seizures. ILAE-preferred treatments in partial-onset seizures are as follows2:

· In adults with partial-onset seizures, carbamazepine and phenytoin are preferred first-line treatments backed by level A evidence. Valproate is another option for these patients, but is backed by level B evidence. Several level C options are available.

· In children, partial-onset seizures are treated with different medications, preferably oxcarbazepine (level A). Although several other options are backed by level C evidence, no other agents are backed by level A or B evidence for children with partial-onset seizures.

· In elderly adults with partial-onset seizures, gabapentin and lamotrigine are preferred treatments, backed by level A evidence. Although use of carbamazepine is backed by level C evidence, no other agents are backed by level A or B evidence for children with partial-onset seizures.

Other guidelines categorize treatments differently. For instance, rather than providing the level of evidence supporting the use of a given medication, the AAN/AES guidelines simply state whether or not a given treatment is an appropriate option for patients with a given type of seizure. From these guidelines, it is evident that lamotrigine and topiramate are treatment options in the largest range of seizure types. Other treatments are recommended for use in a narrower range of conditions. For instance4:

· Gabapentin may be used to treat newly diagnosed partial or mixed seizures as monotherapy, and as adjunctive therapy for continued treatment of partial seizures

· Oxcarbazepine may be used to treat newly diagnosed partial or mixed seizures as monotherapy, and as adjunctive therapy or monotherapy for continued treatment of partial seizures

· Tiagabine, zonisamide, and levetiracetam may be used adjunctively to treat partial seizures in adults

AEDs may also be categorized by the spectrum of epilepsies in which they are used. Some treatments are used only in very specific types of epilepsy. For instance, ethoxsuximide is only used in absence seizures, and methsuximide and acetazolamide are only used for absence seizures and generalized tonic-clonic seizures. Similarly, vigabatrin, ACTH, and prednisone are limited to use in infantile spasms.

Other AEDs are used exclusively for focal epilepsies. AEDs that treat focal epilepsies include oxcarbazepine, carbamazepine, phenobarbital, phenytoin, topiramate, valproate, gapabantin, pregabalin, lacosamide, ezogabine, and perampanel.

The broadest spectrum AEDs, which can be used to treat both focal and generalized epilepsies, include lamotrigine and topiramate, as well as zonisamide, levetiracetam, valproate, rufinamide, felbamate, benzodiazepines, and triple bromides.

Beyond pharmacotherapy, other treatments, including neurostimulation, diet, brain surgery, and other treatment modalities, may be used to optimize seizure control and attain the dual goals of adverse event minimization and quality-of-life optimization. By understanding the spectrum of available treatments, pharmacists can better understand the scope of available treatments and the limitations of current pharmacotherapies for epilepsy.

References

1. Tich SN, Péréon Y. Semiological seizure classification. Epilepsia. 1999;40(4):531.

2. Glauser T, Ben-Menachem E, Bourgeois B, et al. ILAE treatment guidelines: evidence-based analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia. 2006;47(7):1094-1120.

3. NICE. The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care. www.nice.org.uk/guidance/cg137. Accessed December 2014.

4. Ben-Menachem E. AAN/AES guidelines on use of new AEDS. Epilepsy Curr. 2005;5(1):30-32.

5. SIGN. Diagnosis and Management of Epilepsy in Adults. www.sign.ac.uk/guidelines/fulltext/70/. Accessed December 2014.

6. SE Working Group. Treatment of convulsive status epilepticus. Recommendations of the Epilepsy Foundation of America's Working Group on Status Epilepticus. JAMA. 1993;270(7):854-859.

Related Videos
Happy elderly patient with medical health checkup with cardiologist or geriatric doctor. Senior old aging woman with coronary artery heart disease or cardiac illness check-up in clinic - Image credit: Chinnapong | stock.adobe.com
Pharmacist and patient in a retail/community pharmacy setting -- Image credit: Zamrznuti tonovi | stock.adobe.com
Menoapuse spelled with wooden blocks -- Image credit: loran4a | stock.adobe.com
Related Content
Advertisement
Plaque buildup in artery | Image Credit: © SK imagine - stock.adobe.com
May 8th 2025

Obicetrapib Plus Ezetimibe Reduced LDL-C in Patients With or at Risk of Atherosclerotic Cardiovascular Disease

Alexandra Gerlach, Associate Editor
Pharmacists Can Be At the Forefront of Cardio-Kidney-Metabolic Management
May 6th 2025

Pharmacists Can Be At the Forefront of Cardio-Kidney-Metabolic Management

Aislinn Antrim, Managing Editor Craig Beavers, PharmD, FACC, FAHA, FCCP, BCCP, BCPS-AQ Cardiology, CACP
U.S. House of Representatives, Washington, DC USA
May 8th 2025

Coalition of Pharmacy Organizations Urges Congress to Pass ECAPS Legislation

Luke Halpern, Assistant Editor
Pharmacy Focus: Integrating SBIRT in Pharmacies to Combat Substance Use Disorder
March 31st 2025

Pharmacy Focus: Integrating SBIRT in Pharmacies to Combat Substance Use Disorder

Luke Halpern, Assistant Editor
GLP-1 and Side Effects newspaper headlines with magnifying glass
May 8th 2025

Asembia AXS25: Navigating the Transformative Landscape of GLP-1 Medications

Luke Halpern, Assistant Editor
Wegovy injection pen | Image Credit: © Patrick Bay Damsted - stock.adobe.com
May 7th 2025

GLP-1 Drugs Show Promise in Lowering Health Care Costs, Report Says

Alexandra Gerlach, Associate Editor
Related Content
Advertisement
Plaque buildup in artery | Image Credit: © SK imagine - stock.adobe.com
May 8th 2025

Obicetrapib Plus Ezetimibe Reduced LDL-C in Patients With or at Risk of Atherosclerotic Cardiovascular Disease

Alexandra Gerlach, Associate Editor
Pharmacists Can Be At the Forefront of Cardio-Kidney-Metabolic Management
May 6th 2025

Pharmacists Can Be At the Forefront of Cardio-Kidney-Metabolic Management

Aislinn Antrim, Managing Editor Craig Beavers, PharmD, FACC, FAHA, FCCP, BCCP, BCPS-AQ Cardiology, CACP
U.S. House of Representatives, Washington, DC USA
May 8th 2025

Coalition of Pharmacy Organizations Urges Congress to Pass ECAPS Legislation

Luke Halpern, Assistant Editor
Pharmacy Focus: Integrating SBIRT in Pharmacies to Combat Substance Use Disorder
March 31st 2025

Pharmacy Focus: Integrating SBIRT in Pharmacies to Combat Substance Use Disorder

Luke Halpern, Assistant Editor
GLP-1 and Side Effects newspaper headlines with magnifying glass
May 8th 2025

Asembia AXS25: Navigating the Transformative Landscape of GLP-1 Medications

Luke Halpern, Assistant Editor
Wegovy injection pen | Image Credit: © Patrick Bay Damsted - stock.adobe.com
May 7th 2025

GLP-1 Drugs Show Promise in Lowering Health Care Costs, Report Says

Alexandra Gerlach, Associate Editor
Consent Preferences
About Us
Clinical Forums
Advertise
Contact Us
Editorial Staff
Privacy Policy
Terms & Conditions
Do Not Sell My Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.